glp-3 retatrutide 10mg (Reta) Retatrutide 10mg Triple Agonist |

10.1369/0022155415583535 13 BuseJ

This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License

Several nutritional pitfalls commonly occur when individuals begin GLP-1 therapy, potentially compromising health outcomes or treatment efficacy

Vial Size 3

Defined by hepatic steatosis and at least one cardiometabolic risk factor such as type 2 diabetes mellitus (T2DM), obesity, or hypertension, MASLD affects over 30% of the global population

Retatrutide is currently in Phase 3 clinical trials, which means it successfully passed Phase 1 (safety in healthy volunteers) and Phase 2 (efficacy and safety in target population)